Abstract
Multidomain kinases such as c-Src and c-Abl are regulated by complex allosteric interactions involving their noncatalytic SH3 and SH2 domains. Here we show that enhancing natural allosteric control of kinase activity by SH3/linker engagement has long-range suppressive effects on the kinase activity of the c-Abl core. Surprisingly, enhanced SH3/linker interaction also dramatically sensitized the Bcr-Abl tyrosine kinase associated with chronic myelogenous leukemia to small molecule inhibitors that target either the active site or the myristic acid binding pocket in the kinase domain C-lobe. Dynamics analyses using hydrogen exchange mass spectrometry revealed a remarkable allosteric network linking the SH3 domain, the myristic acid binding pocket, and the active site of the c-Abl core, providing a structural basis for the biological observations. These results suggest a rational strategy for enhanced drug targeting of Bcr-Abl and other multidomain kinase systems that use multiple small molecules to exploit natural mechanisms of kinase control.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Binding Sites
-
Cell Line, Tumor
-
Enzyme Activation / drug effects
-
Enzyme Activation / genetics
-
Fusion Proteins, bcr-abl / antagonists & inhibitors
-
Fusion Proteins, bcr-abl / chemistry
-
Fusion Proteins, bcr-abl / genetics
-
Fusion Proteins, bcr-abl / metabolism
-
Humans
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
-
Myristic Acid / chemistry*
-
Protein Kinase Inhibitors / chemistry*
-
Protein-Tyrosine Kinases / antagonists & inhibitors
-
Protein-Tyrosine Kinases / chemistry
-
Protein-Tyrosine Kinases / genetics
-
Protein-Tyrosine Kinases / metabolism
-
Proto-Oncogene Proteins c-abl / antagonists & inhibitors*
-
Proto-Oncogene Proteins c-abl / chemistry*
-
Proto-Oncogene Proteins c-abl / genetics
-
Proto-Oncogene Proteins c-abl / metabolism
-
src Homology Domains
Substances
-
Protein Kinase Inhibitors
-
Myristic Acid
-
Protein-Tyrosine Kinases
-
Fusion Proteins, bcr-abl
-
Proto-Oncogene Proteins c-abl